Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Tagraxofusp-erzs (elzonris) has shown effectiveness in both treatment-naive and previously treated adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), with high rates of successful bridging to hematopoietic stem cell transplantation (HSCT).
• Tagraxofusp represents a significant improvement over traditional induction chemotherapy for BPDCN, particularly in facilitating bridging to SCT, which is often not achieved with standard treatments.
• The drug is approved for use in patients aged 2 years and older, including those newly diagnosed and relapsed/refractory, though pediatric experience is limited and does not provide specific effectiveness outcomes.
• The primary safety concern for tagraxofusp-erzs (elzonris) is the risk of capillary leak syndrome, a potentially fatal condition, necessitating careful patient selection and monitoring.
• The safety of tagraxofusp in pediatric patients is mentioned but not detailed, while in adults, the drug is generally considered safe with the noted risk of capillary leak syndrome.
• There is no population types or subgroups information available in the reviewed studies.